The Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients with Prior Myocardial Infarction and no History of Stroke or TIA: Results from TRA 2 P-TIMI 50 -

The Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients with Prior Myocardial Infarction and no History of Stroke or TIA: Results from TRA 2 P-TIMI 50
Information type: Other primary research
Source: Circulation Research
Specialities: Cardiovascular system disorders
Summary
Pre-specified analysis (n=16,897) found vorapaxar (VX) significantly reduced composite of CV death, MI and stroke vs. placebo, regardless of planned thienopyridine (TP) therapy. Moderate/severe bleeding risk was increased with VX and was not significantly altered by planned TP.
UKMi comment
Vorapaxar was approved in the EU in March 2015 for reducing atherothrombotic events after a myocardial infarction or in peripheral vascular disease. A NICE appraisal will be rescheduled to align with the commercial availability of the product within the UK.
Related links: